| 1 | 13:00-13:05 |
Opening Remarks |
|
||||||||
| 1 | 13:05-13:25 |
FRUSICA‑2 Study Opens a New Chapter for Previously Treated Renal Cell Carcinoma |
|
||||||||||||||
| 2 | 13:25-13:45 |
Stratified Therapy and Whole-Course Management: Building the Blueprint for Diagnosis and Treatment of Advanced Renal Cell Carcinoma |
|
||||||||||||||
| 3 | 13:45-14:05 |
Discussion |
|
||||||||||||||
| 1 | 14:05-14:25 |
Frontline Advances in Immunotherapy for Renal Cell Carcinoma |
|
||||||||||||||
| 2 | 14:25-14:45 |
New Insights into Perioperative Strategies for Renal Cell Carcinoma in the Immunotherapy Era |
|
||||||||||||||
| 3 | 14:45-15:05 |
Discussion |
|
||||||||||||||
| 1 | 15:05-15:10 |
Summary |
|
||||||||
| 1 | 16:00-16:15 |
Opening Remarks |
|
|||||||||||
| 1 | 16:15-16:25 |
Launch Ceremony of the 2027 National Project for Standardized Construction of Precision Diagnosis and Treatment and Recurrence Prevention of Urolithiasis |
|
|||||
| 2 | 16:30-16:40 |
Interpretation of the Chinese Expert Consensus on Metabolic Evaluation and Recurrence Prevention of Urolithiasis |
|
|||||
| 1 | 16:40-16:50 |
Patented Sustained-release Technology and Technical Breakthroughs of Potassium Citrate for Generic Consistency Evaluation |
|
|||||
| 2 | 16:50-17:10 |
Application of Potassium Citrate in Urolithiasis |
|
|||||
| 3 | 17:10-17:20 |
Case Sharing |
|
|||||
| 1 | 17:20-17:45 |
Discussion: 1. Metabolic Assessment: From Guidelines to Clinical Application 2. Nephrolithiasis Prevention: From Concept to Behavior 3. Multi-party Collaboration: From Consensus to Practice |
||||||||||||
| 2 | 17:45-18:00 |
Summary |
|
|||||||||||